Chapter 5 - Clinical Trial Simulation#

Presenter : HeeSeok Yoo#

Introduction#

  • Monte Carlo simulation : example of coin toss

General Steps

Applied to te coin toss example

Specify numerical values for:

- Simulation parameters

Probability of heads = 0.50

- Sample size

10 tosses of the coin

- Analysis/test statistics

Number of heads out of the 10 tosses

For each replication:

1. Generate data

Generate 10 random coin tosses

2. Run Analysis

Count the number of heads out of 10 tosses

3. Keep track of the performance

Keep track of 2 and repeat 1,000 times

  • In Clinical trial, we can’t repeat the trial like coin flip.

  • The Utility of simulation studies in a clinical design prcess has become very important.

Clinical Trial Simulation#

Terms#

  • Operating characteristics - description of how a design performs under various scenarios.

  • Scenario - List of values specifying the ‘true’ underlying parameters, such as true response rates, recuritment rate, etc.

  • Simulation - Repeated analyses of randomly generated datasets drawn under specific assumptions.

  • Simulation report - Written documents that provides the explanation, details, and justification of the simulation study.

  • Trial design - Details about how the trial is conducted.

  • Virtual trial - Clinical trial being simulated in computer.

Overview of Clinical Trial Simulation#

  • The goal of cilnical trial sumulation is to make virtual trial design match as closely as possible how the trial will be conducted.

  • General steps of simulation for an adaptive clinical trial would involve: ** Step 1: Simulate the arrival time of the next patient. ** Step 2: Check the stopping rules to see if the trial should be stopped. ** Step 3: If the trial not stopped, enroll more patients into the nexy interim analysis. ** Step 4: Simulate the patient outcome as a fuction of the treatment. ** Step 5: Repeat steps 1-4

Principles of Simulation-Guided Trial Design#

  • Simulation-guided trial design encourages evaluating multiple design options early to ensure the most efficient and ethical choice is made for each clinical question.

  • Adaptive designs can improve trial success by anticipating potential regrets and adjusting accordingly, serving as a form of ‘insurance’ against trial failure.

Simulation-Guided Design Planning Case Study#

  • Simulation studies help explore the trade-offs between trial designs beyond average behavior.

  • Rather than recommending one design, a Bayesian adaptive approach is used to review different metrics.

Design and Scenario Assumptions#

No.

Trial designs

Scenarios

1

Equal randomisation

Equal treatment effect/response rate (Null)

- 1:1 allocation to E and S

- pS = 0.3 and pE = 0.3

2

RAR with no minimum/maximum allocation

10% higher response rate in E

- At interim analysis, adapt the

- pS = 0.3 and pE = 0.4

allocation probability for E to

probability that E has higher

response rate than S (pE)

- Allocation of S would be 1 − pE

3

RAR with minimum/maximum allocation

20% higher response rate in E

- Same as Design 2 with 10% minimum

- pS = 0.3 and pE = 0.5

and 90% maximal allocation

probabilities, to ensure that the

allocation does not get ‘stuck’

on one study arm

  • Patient enrollment followed a Poisson process with interim analysis every 10 subjects after a 30-subject burn-in.

  • Response probabilities:

    • pS ~ Beta(0.2, 0.8)

    • pE ~ Beta(0.2, 0.8)

  • Stopping rules:

    • Superiority threshold = 0.995

    • Futility threshold = 0.005

    • Ensures Type I error < 3.3% under null

Simulation results#

  • Type I error ~0.03 in Scenario 1 across designs

  • Design 1 has highest power in all scenarios (0.72 in Scenario 3)

  • Early stopping rates and mean sample sizes vary

  • P20 metric introduced: % of trials where ≥20 more patients assigned to SOC

Examination of Singl Virtual Trials#

  • Figures display randomization probabilities over time for virtual trials

  • Design 2 shows large imbalance in some trials, e.g., 172:26 (SOC:E) in null scenario

  • Design 3 mitigates imbalance via min allocation threshold

  • In Scenario 2 and 3, some trials assigned more to inferior treatment → RAR risk

  • P20 exposes ethical risk of RAR misallocating patients

  • Even fixed randomization (Design 1) can show imbalance without blocked randomization

  • Design evaluation must go beyond averages — include worst-case risks

Simulation Reports#

  • Essential for adaptive and complex trials

  • DIA-ADSWG recommends including:

    • Objectives, inputs, design rules

    • Scenario definitions, operating characteristics

    • Discussion and justification of chosen design (Table 5.4)

Simulation Software#

  • Commercial: EAST®, ADDPLAN®, COMPASS®, FACTS

    • Advantages: ready-to-use, no coding required

    • Limitations: cost, limited flexibility for custom designs

  • Open-source (R-based):

    • Notable packages: rpact, MAMS, Mediana, multiarm, adaptr, OCTOPUS, gsDesign

    • Many offer vignette tutorials

    • Available on CRAN and GitHub

Conclusion#

  • Simulation is critical to evaluate trial design operating characteristics

  • Adaptive designs may improve ethics but carry trade-offs

  • No universal best design — simulation helps identify the most efficient and ethical option per research question